advertisement

Topcon

Kasetti RB 8

Showing records 1 to 8 | Display all abstracts from Kasetti RB

95590 Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9
Maddineni P
International journal of molecular sciences 2021; 22:
95603 Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
Kasetti RB; Maddineni P
International journal of molecular sciences 2021; 22:
95590 Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9
Kasetti RB
International journal of molecular sciences 2021; 22:
95603 Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
Kodati B
International journal of molecular sciences 2021; 22:
95590 Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9
Kodati B
International journal of molecular sciences 2021; 22:
95603 Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
Nagarajan B
International journal of molecular sciences 2021; 22:
95590 Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9
Yacoub S; Zode GS
International journal of molecular sciences 2021; 22:
95603 Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
Yacoub S
International journal of molecular sciences 2021; 22:

Issue 22-3

Change Issue


advertisement

Oculus